vs
GENESCO INC（GCO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是GENESCO INC的1.3倍（$772.1M vs $616.2M），Revvity净利率更高（12.7% vs 0.9%，领先11.9%），Revvity同比增速更快（5.9% vs 3.3%），Revvity自由现金流更多（$161.8M vs $-31.5M），过去两年Revvity的营收复合增速更高（9.0% vs -8.7%）
Genesco Inc是总部位于美国田纳西州纳什维尔的上市企业，核心业务为品牌鞋履及配饰零售，同时开展品牌与授权鞋履的批发业务。该公司起源于1924年成立的贾曼鞋业公司，最初为鞋履制造商，1933年更名为通用鞋业，1939年完成上市，目前名称为原企业名的首字母缩写。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GCO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$616.2M
营收增速更快
RVTY
高出2.5%
3.3%
净利率更高
RVTY
高出11.9%
0.9%
自由现金流更多
RVTY
多$193.3M
$-31.5M
两年增速更快
RVTY
近两年复合增速
-8.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $616.2M | $772.1M |
| 净利润 | $5.4M | $98.4M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 1.4% | 14.5% |
| 净利率 | 0.9% | 12.7% |
| 营收同比 | 3.3% | 5.9% |
| 净利润同比 | 128.3% | 3.9% |
| 每股收益（稀释后） | $0.50 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GCORVTY
| Q4 25 | $616.2M | $772.1M | ||
| Q3 25 | $546.0M | $698.9M | ||
| Q2 25 | $474.0M | $720.3M | ||
| Q1 25 | $745.9M | $664.8M | ||
| Q4 24 | $596.3M | $729.4M | ||
| Q3 24 | $525.2M | $684.0M | ||
| Q2 24 | $457.6M | $691.7M | ||
| Q1 24 | $739.0M | $649.9M |
净利润GCORVTY
| Q4 25 | $5.4M | $98.4M | ||
| Q3 25 | $-18.5M | $46.7M | ||
| Q2 25 | $-21.2M | $53.9M | ||
| Q1 25 | $34.4M | $42.2M | ||
| Q4 24 | $-18.9M | $94.6M | ||
| Q3 24 | $-10.0M | $94.4M | ||
| Q2 24 | $-24.3M | $55.4M | ||
| Q1 24 | $27.2M | $26.0M |
毛利率GCORVTY
| Q4 25 | 46.8% | — | ||
| Q3 25 | 45.8% | 53.6% | ||
| Q2 25 | 46.7% | 54.5% | ||
| Q1 25 | 46.9% | 56.5% | ||
| Q4 24 | 47.8% | — | ||
| Q3 24 | 46.8% | 56.3% | ||
| Q2 24 | 47.3% | 55.7% | ||
| Q1 24 | 46.3% | 54.6% |
营业利润率GCORVTY
| Q4 25 | 1.4% | 14.5% | ||
| Q3 25 | -2.6% | 11.7% | ||
| Q2 25 | -5.9% | 12.6% | ||
| Q1 25 | 6.2% | 10.9% | ||
| Q4 24 | 1.7% | 16.3% | ||
| Q3 24 | -2.0% | 14.3% | ||
| Q2 24 | -7.0% | 12.4% | ||
| Q1 24 | 5.0% | 6.8% |
净利率GCORVTY
| Q4 25 | 0.9% | 12.7% | ||
| Q3 25 | -3.4% | 6.7% | ||
| Q2 25 | -4.5% | 7.5% | ||
| Q1 25 | 4.6% | 6.4% | ||
| Q4 24 | -3.2% | 13.0% | ||
| Q3 24 | -1.9% | 13.8% | ||
| Q2 24 | -5.3% | 8.0% | ||
| Q1 24 | 3.7% | 4.0% |
每股收益（稀释后）GCORVTY
| Q4 25 | $0.50 | $0.86 | ||
| Q3 25 | $-1.79 | $0.40 | ||
| Q2 25 | $-2.02 | $0.46 | ||
| Q1 25 | $3.16 | $0.35 | ||
| Q4 24 | $-1.76 | $0.77 | ||
| Q3 24 | $-0.91 | $0.77 | ||
| Q2 24 | $-2.23 | $0.45 | ||
| Q1 24 | $2.29 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.0M | $919.9M |
| 总债务越低越好 | $89.5M | — |
| 股东权益账面价值 | $513.8M | $7.3B |
| 总资产 | $1.5B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资GCORVTY
| Q4 25 | $27.0M | $919.9M | ||
| Q3 25 | $41.0M | $931.4M | ||
| Q2 25 | $21.7M | $991.8M | ||
| Q1 25 | $34.0M | $1.1B | ||
| Q4 24 | $33.6M | $1.2B | ||
| Q3 24 | $45.9M | $1.2B | ||
| Q2 24 | $19.2M | $2.0B | ||
| Q1 24 | $35.2M | $1.7B |
总债务GCORVTY
| Q4 25 | $89.5M | — | ||
| Q3 25 | $71.0M | — | ||
| Q2 25 | $121.0M | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $100.1M | — | ||
| Q3 24 | $77.8M | — | ||
| Q2 24 | $59.4M | — | ||
| Q1 24 | $34.7M | — |
股东权益GCORVTY
| Q4 25 | $513.8M | $7.3B | ||
| Q3 25 | $506.4M | $7.4B | ||
| Q2 25 | $522.2M | $7.6B | ||
| Q1 25 | $547.0M | $7.6B | ||
| Q4 24 | $516.9M | $7.7B | ||
| Q3 24 | $532.6M | $7.9B | ||
| Q2 24 | $548.5M | $7.9B | ||
| Q1 24 | $571.2M | $7.8B |
总资产GCORVTY
| Q4 25 | $1.5B | $12.2B | ||
| Q3 25 | $1.4B | $12.1B | ||
| Q2 25 | $1.4B | $12.4B | ||
| Q1 25 | $1.3B | $12.4B | ||
| Q4 24 | $1.4B | $12.4B | ||
| Q3 24 | $1.4B | $12.8B | ||
| Q2 24 | $1.3B | $13.4B | ||
| Q1 24 | $1.3B | $13.4B |
负债/权益比GCORVTY
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.19× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-12.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-31.5M | $161.8M |
| 自由现金流率自由现金流/营收 | -5.1% | 21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 2.6% |
| 现金转化率经营现金流/净利润 | -2.41× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $23.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流GCORVTY
| Q4 25 | $-12.9M | $182.0M | ||
| Q3 25 | $86.3M | $138.5M | ||
| Q2 25 | $-101.0M | $134.3M | ||
| Q1 25 | $117.0M | $128.2M | ||
| Q4 24 | $-23.1M | $174.2M | ||
| Q3 24 | $27.7M | $147.9M | ||
| Q2 24 | $-33.7M | $158.6M | ||
| Q1 24 | $118.3M | $147.6M |
自由现金流GCORVTY
| Q4 25 | $-31.5M | $161.8M | ||
| Q3 25 | $71.7M | $120.0M | ||
| Q2 25 | $-119.9M | $115.5M | ||
| Q1 25 | $103.3M | $112.2M | ||
| Q4 24 | $-36.2M | $149.8M | ||
| Q3 24 | $19.8M | $125.6M | ||
| Q2 24 | $-40.1M | $136.6M | ||
| Q1 24 | $107.8M | $129.7M |
自由现金流率GCORVTY
| Q4 25 | -5.1% | 21.0% | ||
| Q3 25 | 13.1% | 17.2% | ||
| Q2 25 | -25.3% | 16.0% | ||
| Q1 25 | 13.8% | 16.9% | ||
| Q4 24 | -6.1% | 20.5% | ||
| Q3 24 | 3.8% | 18.4% | ||
| Q2 24 | -8.8% | 19.7% | ||
| Q1 24 | 14.6% | 20.0% |
资本支出强度GCORVTY
| Q4 25 | 3.0% | 2.6% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 4.0% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 2.2% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 1.4% | 3.2% | ||
| Q1 24 | 1.4% | 2.7% |
现金转化率GCORVTY
| Q4 25 | -2.41× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 3.40× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 4.35× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GCO
| Journeys Group Segment | $376.7M | 61% |
| Schuh Group Segment | $123.8M | 20% |
| Johnston And Murphy Group Segment | $81.2M | 13% |
| Genesco Brands Segment | $34.6M | 6% |
| Store Restructuring | $3.9M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
